The Gamaleya research center expects the effectiveness of its vaccine against the coronavirus, Sputnik V, to increase further, the center’s deputy director of science, Denis Logunov, said on Monday.
Read also: Four test volunteers who received a COVID-19 vaccine from Pfizer developed Bell’s palsy
According to the institute, the vaccine against Sputnik V against COVID-19 is likely to provide up to two years of immunity against COVID-19, compared to the four or five months of immunity that can be achieved using the vaccine produced by Pfizer and BioNTech.
“As for our vaccine and the platform on which it was created, the Ebola vaccine, there is experimental evidence that using this platform, using similar preparation methods, provides protection for at least two years, maybe more. It’s hard to say how long the Pfizer vaccine will give immunity, but based on the overall results of such vaccines, it should be thought that the period of protection will be no more than four to five months, although this requires experimental data, “Alexander Gintsburg, head of the Russian research institute Gamaleya , he said.
Read also: A new variant of coronavirus identified in the United Kingdom; London in Tier 3 blockade
According to Logunov, the overall efficacy of 91.4 percent was calculated for people who received both doses of vaccine. There are 21 days between the two injections, so the calculations considered the cases from 21 days onwards.
Read also: US administers first vaccine against coronavirus; Donald Trump congratulates Americans
“Obviously, it has shown high efficacy, but as we have been calculating since 21 days and including the cases, we also hope that if we increase the vaccination period to 28, 35, 42 days, the efficacy numbers can increase,” Logunov told informed.
“The data analysis at the third and final checkpoint of the clinical trials of a vaccine against Sputnik V confirmed its efficacy of more than 90 percent. Clinical trials demonstrated this in the three consecutive statistically important points described in the trial protocol,” noted RDIF Chief Executive Officer Kirill Dmitriev.
The joint statement read that the analysis of the efficacy of the Sputnik V vaccine at the endpoint was made on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases).
“The ratio of the placebo group to the vaccinated group is 1 to 3,” the joint statement said.
On Monday, more than 26,000 volunteers were vaccinated at 29 medical centers in Russia, as part of ongoing clinical trials. Phase 3 trials are currently ongoing in countries such as Belarus, the United Arab Emirates (UAE) and Venezuela, while Phase 2/3 trials are being conducted in India.
The statement mentioned that no unexpected adverse events were now identified as part of the research, although some of those vaccinated had immediate adverse adverse events such as pain at the injection site and flu symptoms, including fever, weakness, fatigue. , and headache.
“The new data on the effectiveness of the Gamaleya Center vaccine is extremely encouraging. Today it became clear to everyone that the end of the pandemic is possible only after the mass vaccination of the entire global population. In this regard, ensure equal access to effective and safe vaccines, including the Sputnik V, for people in every country should be the target of foreign regulatory bodies and international organizations, ”said Mihaail Murashko, health minister of the Russian Federation.
Russia became the first country to register the world’s first COVID-19 vaccine on August 11, Sputnik V, named after Russia’s first satellite.
(With agency inputs)